Methods and Compositions for Treatment of Angiogenic Disorders Using Anti-VEGF Agents
AssigneeThe Regents of the University of California
InventorNapoleone Ferrara
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for treatment of angiogenic disorders using anti-VEGF agents. The anti-VEGF agents comprise VEGF binding domains and have the ability to bind vitreous. Provided are exemplary embodiments of Fc-IgG fusion proteins with VEGF binding domains with strong heparin-binding characteristics, strong inhibition of VEGF mitogenic activity, and improved pharmacokinetics, namely longer half-lives of the anti-VEGF agents and consequently less frequent dosing.
Claims41
An anti-VEGF agent comprising a VEGF binding portion operatively linked to a Fc-IgG, wherein the VEGF binding portion comprises at least one VEGF binding domain that is an IgG-like domain 2 of VEGFR-1, and wherein the anti-VEGF agent has a VEGF-stimulated mitogenesis-inhibiting ability greater than aflibercept.
The method of claim 20, wherein the said affected tissue or organ is an eye.
An anti-Vascular Endothelial Growth Factor (VEGF) agent comprising a VEGF binding portion operatively linked to a Fc-IgG, wherein the VEGF binding portion comprises an IgG-like domain 2 of VEGFR-1 and an IgG-like domain 4 of VEGFR-1, and wherein the VEGF binding portion does not contain an IgG-like domain 3 of VEGFR-1.
Dependencies are inferred from the claim text.